Research Summary

COVID-19 mRNA Vaccines Linked to Better Outcomes with Immune Checkpoint Inhibitors in NSCLC and Melanoma

Anthony Calabro, MA

Key Highlights

  • COVID-19 mRNA vaccination within 100 days of immune checkpoint inhibitor (ICI) initiation was linked to improved survival in patients with stage III/IV Non-small cell lung cancer and metastatic melanoma.
  • Preclinical models showed spike mRNA–lipid nanoparticles induced type I interferon–dependent priming of tumor-reactive CD8+ T cells and synergy with PD-(L)1 blockade.
  • Recent vaccination correlated with higher PD-L1 tumor expression, including more patients exceeding the ≥50% TPS threshold.

A Nature study from The University of Texas MD Anderson Cancer Center (Houston, TX) reports that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint inhibitors (ICIs). Through retrospective cohort analyses, preclinical modeling, and human immune profiling, investigators found that COVID-19 mRNA vaccination near ICI initiation was associated with immune activation, increased PD-L1 expression, and improved clinical outcomes.

Researchers reviewed data from patients with stage III/IV non–small cell lung cancer (NSCLC) and metastatic melanoma treated at MD Anderson between 2015 and 2022. They compared overall and progression-free survival in patients who received a COVID-19 mRNA vaccine within 100 days of starting ICI therapy versus those who did not. Multivariable and sensitivity analyses—including propensity score matching—controlled for clinical and demographic variables. Separate cohorts evaluated PD-L1 tumor proportion score (TPS) by vaccination timing. Mouse models and human volunteer studies assessed mechanistic pathways.

Study Findings

Among 180 vaccinated and 704 unvaccinated patients with NSCLC, vaccination within 100 days of ICI initiation was associated with longer median overall survival (37.3 vs 20.6 months) and higher 3-year survival (55.7% vs 30.8%; adjusted HR, 0.51; 95% CI, 0.37–0.71; P < .001). Results were consistent across stages and analyses. Among 43 vaccinated and 167 unvaccinated patients with metastatic melanoma, vaccination correlated with improved overall survival (adjusted HR, 0.37; P = .0048) and progression-free survival (adjusted HR, 0.63; P = .0383).

Recent vaccination (<100 days before biopsy) was associated with higher mean PD-L1 TPS in patients with NSCLC (31% vs 25% unvaccinated; P = .045) and a greater proportion achieving TPS ≥50% (36% vs 28%; P = .03). Similar trends were observed across other tumor types.

In preclinical models, spike mRNA–lipid nanoparticles enhanced ICI efficacy through type I interferon signaling, increasing activation of dendritic cells and expansion of tumor-reactive CD8+ T cells. In healthy volunteers, IFNα levels rose nearly 280-fold 24 hours after vaccination, accompanied by transient innate and adaptive immune activation.

Clinical Implications

The authors reported that the timing of SARS-CoV-2 mRNA vaccination relative to ICI initiation was linked to improved survival and higher PD-L1 expression, including in immunologically “cold” tumors. These findings suggest that mRNA vaccination can transiently reset immune responsiveness to favor ICI efficacy.

Expert Commentary

“These findings define a role for widely available vaccines for enhancing the efficacy of cancer immunotherapy,” the authors concluded. “Although we focus on a single therapeutic due to its wide availability, these data could pave the way for other universal mRNA therapeutics specifically designed to reset patient immune systems for enhanced response to immunotherapy.”

This study demonstrated that SARS-CoV-2 mRNA vaccination near ICI initiation is associated with immune activation, increased PD-L1 expression, and better survival outcomes across cancers. The results identify a potential role for existing mRNA vaccines as modulators of antitumor immunity.

Reference:
Grippin AJ, Marconi C, Copling S, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. Published online October 22, 2025. doi:10.1038/s41586-025-09655-y